FATE Q2 2018 Earnings — Fate Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FATEFate Therapeutics, Inc.

$142M

Q2 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M+0.1% YoY

Gross Profit

-$16M-1537.4% margin

Operating Income

-$20M-1909.0% margin

Net Income

-$20M-1913.7% margin

EPS (Diluted)

$-0.37

QoQ Revenue Growth

+0.1%

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$12M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$83M

Total Liabilities

$31M

Stockholders' Equity

$52M

Cash & Equivalents

$36M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$1M	+0.1%
Gross Profit	-$16M	-$7M	-128.8%
Operating Income	-$20M	-$10M	-104.9%
Net Income	-$20M	-$10M	-103.8%